含西地尼布方案治疗晚期实体瘤疗效及安全性的Meta分析

发布时间：2018-11-16 17:49

【摘要】：目的采用Meta分析法系统评价含西地尼布方案治疗晚期实体瘤的疗效及安全性。方法检索Pub Med、Cochrane Library、EMBase、ASCO Abstract、万方、知网、维普等数据库,收集有关含西地尼布方案治疗晚期实体瘤的随机对照试验(RCT),按纳入、排除标准进行筛选、资料提取及方法学质量评价,采用Revman 5.3软件进行Meta分析,结局指标为无进展生存期(PFS)、总生存期(OS)、客观缓解率(ORR)及≥3级不良反应。结果共纳入9项RCT,包括6种实体瘤和2 345例患者。Meta分析结果显示,与不含西地尼布方案组相比,含西地尼布方案组在PFS(HR=0.78,95%CI:0.71~0.85,P0.000 01)方面差异有显著意义,效果更优;但在OS(HR=0.91,95%CI:0.81~1.02,P=0.12)及ORR(RR=1.21,95%CI:0.97~1.51,P=0.09)方面,两组无显著差异。在≥3级不良反应方面,含西地尼布方案组增加了腹泻(RR=4.06,95%CI:2.97~5.54,P0.000 01)、疲乏(RR=1.91,95%CI:1.49~2.54,P0.000 01)、高血压(RR=3.55,95%CI:2.54~4.96,P0.00 001)、食欲不振(RR=4.05,95%CI:2.31~7.07,P0.000 01)、中性粒细胞减少(RR=1.31,95%CI:1.14~1.50,P=0.000 2)、白细胞减少(RR=1.63,95%CI:1.09~2.43,P=0.02)和血小板减少(RR=1.68,95%CI:1.31~2.14,P0.000 1)事件的发生率。外周感觉神经障碍(RR=1.42,95%CI:0.91~2.23,P=0.12)、贫血(RR=1.13,95%CI:0.51~2.47,P=0.77)和恶心(RR=1.46,95%CI:0.56~3.77,P=0.44)事件的发生率无显著差异。结论含西地尼布方案能够延长晚期实体瘤患者的PFS,但对OS及ORR并无明显改善,同时含西地尼布方案增加了不良反应的发生。
[Abstract]:Objective to evaluate the efficacy and safety of cidenib regimen in the treatment of advanced solid tumors by Meta analysis. Methods the databases of Pub Med,Cochrane Library,EMBase,ASCO Abstract, Wanfang, Zhiwang and Wiper were searched, and (RCT), of randomized controlled trials containing cidenib regimen for the treatment of advanced solid tumors were collected and screened according to the inclusive and exclusion criteria. Data extraction and methodological quality evaluation were performed with Revman 5.3 software for Meta analysis. The outcome indexes were (OS), objective remission rate (ORR) and 鈮，

本文编号：2336204